Life Sciences Times, Author at Life Sciences Times

Affinia Therapeutics Raises $40 Million Series C to Advance Next-Generation Gene Therapies for Cardiovascular and Neurological Diseases

October 7, 2025

RevBio Awarded $2.2 Million NIH Grant to Advance Minimally Invasive Use of TETRANITE® for Treating Spine Fractures

October 6, 2025

Monash University Launches Boston Hub to Accelerate Global Biotech Collaborations and Licensing

October 2, 2025

THIS WEEK'S STORIES

Affinia Therapeutics Raises $40 Million Series C to Advance Next-Generation Gene Therapies for Cardiovascular and Neurological Diseases

October 7, 2025

Samuel Merritt University Sets January 5, 2026 Grand Opening for New Downtown Oakland Flagship Campus

October 6, 2025

Kernal Bio Relocates to Lilly Gateway Labs to Advance In Vivo Cell Therapies

October 3, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Gunze Medical Signs Exclusive Distribution Agreement with HistoSonics for Noninvasive Histotripsy Platform in Japan

Haleon Partners with Salesforce to Enhance Global Customer Engagement Using AI-Powered Life Sciences Cloud

Mikael Dolsten, M.D., Ph.D., Named Chairman of TRIO Pharmaceuticals

Jefferson River Capital Launches Jefferson Life Sciences, a New Early-Stage Investment Firm Focused on Human Health Innovation

EDITOR PICKS

Affinia Therapeutics Raises $40 Million Series C to Advance Next-Generation Gene Therapies for Cardiovascular and Neurological Diseases

RevBio Awarded $2.2 Million NIH Grant to Advance Minimally Invasive Use of TETRANITE® for Treating Spine Fractures

Monash University Launches Boston Hub to Accelerate Global Biotech Collaborations and Licensing

THIS WEEK'S STORIES

Affinia Therapeutics Raises $40 Million Series C to Advance Next-Generation Gene Therapies for Cardiovascular and Neurological Diseases

Samuel Merritt University Sets January 5, 2026 Grand Opening for New Downtown Oakland Flagship Campus

Kernal Bio Relocates to Lilly Gateway Labs to Advance In Vivo Cell Therapies

POPULAR CATEGORY

ABOUT US

FOLLOW US